Antiemetics: American Society of Clinical Oncology Focused Guideline Update | Zendy

Paul J. Hesketh | Zendy; Kari Bohlke | Zendy; Gary H. Lyman | Zendy; Ethan Basch | Zendy; Maurice Chesney | Zendy; Rebecca Clark-Snow | Zendy; Michael Danso | Zendy; Karin Jordan | Zendy; Mark R. Somerfield | Zendy; Mark G. Kris | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antiemetics: American Society of Clinical Oncology Focused Guideline Update

Author(s) -

Paul J. Hesketh,

Kari Bohlke,

Gary H. Lyman,

Ethan Basch,

Maurice Chesney,

Rebecca Clark-Snow,

Michael Danso,

Karin Jordan,

Mark R. Somerfield,

Mark G. Kris

Publication year - 2015

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2015.64.3635

Subject(s) - medicine , clinical oncology , guideline , oncology , family medicine , intensive care medicine , cancer , pathology

To update a key recommendation of the American Society of Clinical Oncology antiemetic guideline. This update addresses the use of the oral combination of netupitant (a neurokinin 1 [NK1] receptor antagonist) and palonosetron (a 5-hydroxytryptamine-3 [5-HT3] receptor antagonist) for the prevention of acute and delayed nausea and vomiting in patients receiving chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research